aspirin has been researched along with avapro in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Khan, BV; Khan, QA; Lauten, WB; Lerakis, S; Parthasarathy, S; Rahman, ST; Rajagopalan, S | 1 |
| Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S | 1 |
| Meinertz, T | 1 |
| Cairns, JA; Gent, M; Hirsh, J; Marler, J; Pogue, J; Pritchett, EL; Wittes, J; Wyse, DG | 1 |
| Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S | 1 |
| Chen, CP; Seet, RC | 1 |
| Ahmad, SJ; Akhtar, M; Islam, F; Khanam, R; Pillai, KK; Pratap, R | 1 |
| Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S | 1 |
| Kamal, AK; Khan, M | 1 |
| Hart, RG | 1 |
| Cao, J; Cui, H; Fan, L; Hu, GL; Leng, WX; Liu, AJ; Lu, XC; Wang, X | 1 |
| Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S | 1 |
| Chen, YL; Hsu, CH; Lau, SC; Liu, IC; Pei, D; Yu, SM | 1 |
| Benavente, O; Connolly, SJ; Hart, RG; Pearce, LA; Perera, KS; Sharma, M | 1 |
| Bibby, BM; Christensen, KL; Jensen, JD; Jespersen, B; Kjaergaard, KD; Peters, CD | 1 |
| Attakora, J; Donkoh, IE; Ephraim, RKD; Essuman, G; Okyere, I; Okyere, P; Serwaa, D | 1 |
3 review(s) available for aspirin and avapro
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clinical Trials Data Monitoring Committees; Clopidogrel; Decision Making; Female; Humans; Irbesartan; Male; Prognosis; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tetrazoles; Ticlopidine; Treatment Outcome | 2008 |
Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
Topics: Antihypertensive Agents; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Humans; Irbesartan; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Tetrazoles; Ticlopidine; Treatment Outcome | 2009 |
6 trial(s) available for aspirin and avapro
| Article | Year |
|---|---|
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Humans; International Normalized Ratio; Irbesartan; Platelet Aggregation Inhibitors; Risk Factors; Severity of Illness Index; Stroke; Tetrazoles; Ticlopidine | 2006 |
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cerebral Hemorrhage; Clinical Protocols; Clopidogrel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Irbesartan; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Warfarin | 2008 |
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Irbesartan; Kaplan-Meier Estimate; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Vitamin K | 2010 |
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Female; Heart Failure; Humans; Irbesartan; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Tetrazoles; Thromboembolism; Ticlopidine; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Clopidogrel; Female; Humans; Irbesartan; Male; Middle Aged; Platelet Aggregation Inhibitors; Predictive Value of Tests | 2018 |
High-sensitivity Troponin T in hemodialysis patients: a randomized placebo-controlled sub-study investigating angiotensin-II-blockade, variation over time and associations with clinical outcome.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Irbesartan; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Risk Factors; Time Factors; Troponin T; Vascular Stiffness | 2020 |
14 other study(ies) available for aspirin and avapro
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Atorvastatin; Biphenyl Compounds; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Interleukin-6; Irbesartan; Isoquinolines; Male; Middle Aged; Monocytes; Platelet Aggregation Inhibitors; Pyrroles; Quinapril; Tetrahydroisoquinolines; Tetrazoles | 2003 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Intracranial Embolism; Irbesartan; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tetrazoles; Thromboembolism; Ticlopidine | 2007 |
Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Aspirin; Biphenyl Compounds; Brain Ischemia; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Infarction, Middle Cerebral Artery; Irbesartan; Male; Motor Activity; Oxidative Stress; Photomicrography; Rats; Rats, Wistar; Tetrazoles; Thiobarbituric Acid Reactive Substances | 2011 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cerebral Hemorrhage; Clopidogrel; Evidence-Based Medicine; Follow-Up Studies; Humans; Hypertension; Irbesartan; Platelet Aggregation Inhibitors; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Warfarin | 2011 |
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Clopidogrel; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Irbesartan; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Stroke; Tetrazoles; Ticlopidine | 2011 |
Irbesartan does not influence the antiplatelet effect of aspirin in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arachidonic Acid; Aspirin; Biphenyl Compounds; Collagen; Drug Interactions; Irbesartan; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Inbred SHR; Tetrazoles | 2012 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; Biphenyl Compounds; Carotid Stenosis; Clonazepam; Coronary Artery Disease; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Gabapentin; gamma-Aminobutyric Acid; Humans; Hypertension; Irbesartan; Male; Parkinson Disease; Quality of Life; Restless Legs Syndrome; Sleep; Tetrazoles; Treatment Outcome | 2017 |
Conservative therapy is associated with worse clinical features and biochemical derangements than renal replacement therapy: a retrospective study in Kumasi, Ghana.
Topics: Adult; Aspirin; Bisoprolol; Conservative Treatment; Furosemide; Ghana; Humans; Irbesartan; Kidney Failure, Chronic; Lisinopril; Metformin; Middle Aged; Nifedipine; Ranitidine; Renal Replacement Therapy; Retrospective Studies; Sodium | 2022 |